Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
14 févr. 2024 07h00 HE | Cogent Biosciences, Inc.
Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials Cogent...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
05 févr. 2024 09h00 HE | Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
09 janv. 2024 08h00 HE | Cogent Biosciences, Inc.
Plan to initiate global, registration-directed SUMMIT Part 2 study of bezuclastinib in NonAdvSM patients during 1H 2024; present results from complete SUMMIT Part 1 at 2024 AAAAI annual conference in...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 08h00 HE | Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
11 déc. 2023 07h55 HE | Cogent Biosciences, Inc.
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose  Nearly all patients achieved at...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
09 déc. 2023 13h30 HE | Cogent Biosciences, Inc.
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
07 déc. 2023 09h00 HE | Cogent Biosciences, Inc.
Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
04 déc. 2023 08h00 HE | Cogent Biosciences, Inc.
- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Additional clinical data update from APEX Part 1 in patients with Advanced...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
29 nov. 2023 08h00 HE | Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
02 nov. 2023 09h00 HE | Cogent Biosciences, Inc.
SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation SUMMIT Part I completed upsized enrollment during Q3; SUMMIT Part 2...